Head-to-head · WeighScore
CoreAge Rx vs Vitara RX
By GLP-1 ScorecardUpdated
Score comparison
CoreAge Rx has the higher recorded score — 89.5/100 to 86/100.
CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
CoreAge Rx scores 89.5/100 (B+).
Before you choose
Before comparing the headline prices, the CoreAge Rx review and the Vitara RX review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, CoreAge Rx vs VivioMD and Cost Plus Drugs vs Vitara RX compare each of them with another graded program, and the list of alternatives to CoreAge Rx ranks the programs closest to CoreAge Rx on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | CoreAge Rx | Vitara RX |
|---|---|---|
| WeighScore | 89.5/100 | 86/100 |
| Grade | B+ | B |
| Site position | #1 | #10 |
| Semaglutide | Product page from $79/mo; navigation $99. Confirm selected quote. | Advertised from $99/month with an annual plan and discount code ($279 reference); conflicting displays—confirm selected charge. |
| Tirzepatide | From $129/mo advertised; confirm selected charge, supply and renewal. | Advertised from $198/month with an annual plan and discount code ($389 reference); conflicting displays—confirm selected charge. |
| Coverage | US only; therapy-specific state restrictions apply | Site lists 49 states, Alaska omitted; confirm medication-specific availability |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #1 · B+
Strengths
- Current product pages advertise starting prices of $79 for semaglutide and $129 for tirzepatide
- Advertises the same price across doses and no membership fee
- Publishes cancellation, fulfillment and refund rules and a way to request the assigned pharmacy
What to consider
- Starting prices vary across public displays and do not establish a selected invoice or usable prescription supply
- FAQ no-rebill and payment-timing statements differ from the subscription and order policy
- FAQ promises a full rejection refund, while policy retains an applicable $50–$100 consultation fee after review begins
- Refund policy makes orders final after approval and pharmacy transmission; Terms also refer to review completion/transmission with policy exceptions. Confirm the cutoff and separate thirty-day documentation limit.
- Actual clinician, dispenser, physical compounder, lab cost and treatment-state eligibility need confirmation
Strengths
- Named compounded semaglutide and tirzepatide offerings
- Ongoing provider messaging advertised
- Terms allow directing prescriptions to another pharmacy
What to consider
- Prices changed with a November site rebuild; annual-plan and discount-code conditions need confirming
- FAQ, terms and returns pages cited earlier no longer load
- Published list omitted Alaska
- Refrigeration instructions conflict with the returns policy
- No universal lab schedule or testing price established
- Website policy descriptions leave clinical and dispensing roles unclear
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.